標題: Titlebook: Dose-Finding Designs for Early-Phase Cancer Clinical Trials; A Brief Guidebook to Takashi Daimon,Akihiro Hirakawa,Shigeyuki Matsui Book 201 [打印本頁] 作者: ED431 時間: 2025-3-21 16:35
書目名稱Dose-Finding Designs for Early-Phase Cancer Clinical Trials影響因子(影響力)
書目名稱Dose-Finding Designs for Early-Phase Cancer Clinical Trials影響因子(影響力)學科排名
書目名稱Dose-Finding Designs for Early-Phase Cancer Clinical Trials網(wǎng)絡公開度
書目名稱Dose-Finding Designs for Early-Phase Cancer Clinical Trials網(wǎng)絡公開度學科排名
書目名稱Dose-Finding Designs for Early-Phase Cancer Clinical Trials被引頻次
書目名稱Dose-Finding Designs for Early-Phase Cancer Clinical Trials被引頻次學科排名
書目名稱Dose-Finding Designs for Early-Phase Cancer Clinical Trials年度引用
書目名稱Dose-Finding Designs for Early-Phase Cancer Clinical Trials年度引用學科排名
書目名稱Dose-Finding Designs for Early-Phase Cancer Clinical Trials讀者反饋
書目名稱Dose-Finding Designs for Early-Phase Cancer Clinical Trials讀者反饋學科排名
作者: 現(xiàn)存 時間: 2025-3-21 23:29
Model-Based Designs Considering Toxicity Alone,oses, and originate from the continual reassessment method (CRM). The present chapter provides a detailed description of the concepts, theories, properties, and advantages and disadvantages of the CRM, and also overview designs that are related to the CRM or that constitute extended versions of this method.作者: concubine 時間: 2025-3-22 03:18
Model-Assisted Designs Considering Toxicity Alone, before trial initiation. The model-assisted designs considering toxicity alone include, e.g., the modified toxicity probability interval (mTPI) design and its improved design (the mTPI-2 design), Bayesian optimal interval design, and keyboard design. In this chapter, we overview these designs and discuss related topics.作者: 處理 時間: 2025-3-22 08:00
Designs for Early-Phase Immunotherapeutic Agent Trials,ical to successful treatment. Such doses are found by considering the outcome related to the immune response in addition to the toxicity and efficacy outcomes. This chapter reviews several dose-finding designs for early-phase immunotherapy trials.作者: LINE 時間: 2025-3-22 11:36 作者: inquisitive 時間: 2025-3-22 15:45 作者: inquisitive 時間: 2025-3-22 19:22 作者: HACK 時間: 2025-3-22 21:16
Book 2019book or handbook for graduate students and practitioners in biostatistics and clinical investigators who are involved in designing, conducting, monitoring, and analyzing dose-finding trials. The book will also provide an overview of advanced topics and discussions in this field for the benefit of re作者: pancreas 時間: 2025-3-23 03:10 作者: 不容置疑 時間: 2025-3-23 06:48 作者: A保存的 時間: 2025-3-23 11:27 作者: 詞匯 時間: 2025-3-23 17:55 作者: Occlusion 時間: 2025-3-23 20:49 作者: Plaque 時間: 2025-3-23 22:36 作者: 維持 時間: 2025-3-24 04:26 作者: 的事物 時間: 2025-3-24 09:20 作者: 推崇 時間: 2025-3-24 13:38
Jes Fenger,Ole Hertel,Finn Palmgrenity and efficacy monotonically increase with increasing dose. This is because the MTD is expected to produce maximal efficacy under admissible toxicity; thus, this dose is basically adopted as the optimal dose in the subsequent phase II and III trials. However, this paradigm is not necessarily suita作者: 燈絲 時間: 2025-3-24 17:03
Olf Herbarth,Uwe Schlink,Matthias Richter This therapy can also be regarded as a type of biological therapy that uses substances made from living organisms to treat cancer, because it employs white blood cells and organs and tissues of the lymph system. Therefore, in cancer immunotherapy, determination of biologically optimal doses is crit作者: Blazon 時間: 2025-3-24 19:49 作者: 座右銘 時間: 2025-3-25 02:58
https://doi.org/10.1007/978-4-431-55585-8Adaptive Design; Cancer; Dose Finding; Phase I; Phase I/II作者: 別炫耀 時間: 2025-3-25 05:00 作者: Atheroma 時間: 2025-3-25 09:29
Early-Phase Cancer Clinical Trials,administered to a cancer patient, so as to obtain the highest efficacy while maintaining admissible toxicity. Thus, in oncology, early-phase trials for anticancer agents are also called “dose-finding” trials. For a chemotherapeutic or cytotoxic agent, classically, the OD is determined in the phase I作者: gene-therapy 時間: 2025-3-25 14:26 作者: ARC 時間: 2025-3-25 18:22
Model-Based Designs Considering Toxicity Alone, trials can be classified as rule-/algorithm- or model-based designs. In Chap. ., we focused on rule-based designs; in the present chapter, we focus on model-based designs. Model-based designs assume a certain statistical model for the monotonic dose–toxicity relationship to borrow strength across d作者: evasive 時間: 2025-3-25 22:40 作者: Occlusion 時間: 2025-3-26 03:06 作者: 侵略 時間: 2025-3-26 05:00 作者: –LOUS 時間: 2025-3-26 09:22 作者: Ringworm 時間: 2025-3-26 15:01 作者: 食品室 時間: 2025-3-26 18:42
Mathematics and Its Applicationsmay not hold for molecularly targeted or cytostatic agents, or for immunotherapeutic agents (IAs). The ODs of such agents are found in phase I/II trials, in which both toxicity and efficacy are evaluated to determine the dose that yields the highest efficacy and admissible toxicity, or the dose that作者: 漂亮 時間: 2025-3-27 00:13 作者: Esalate 時間: 2025-3-27 02:28 作者: predict 時間: 2025-3-27 05:26 作者: 改正 時間: 2025-3-27 09:49 作者: Processes 時間: 2025-3-27 14:35
9樓作者: 炸壞 時間: 2025-3-27 18:05
9樓作者: FAWN 時間: 2025-3-27 22:09
9樓作者: Heart-Attack 時間: 2025-3-28 02:08
10樓作者: curettage 時間: 2025-3-28 06:42
10樓作者: Freeze 時間: 2025-3-28 11:31
10樓作者: 嚴峻考驗 時間: 2025-3-28 15:41
10樓
